Abstract：
Despite widespread vaccination rates, we are living with high transmission rates of SARS-CoV-2. Although overall hospitalisation rates are falling, the risk of serious infection remains high for patients who are immunocompromised because of haematological malignancies. In light of the ongoing pandemic and the development of multiple agents for treatment, representatives from the Haematology Society of Australia and New Zealand and infectious diseases specialists have collaborated on this consensus position statement regarding COVID-19 management in patients with haematological disorders. It is our recommendation that both patients with haematological malignancies and treating specialists be educated regarding the preventive and treatment options available and that patients continue to receive adequate vaccinations, keeping in mind the suboptimal vaccine responses that occur in haematology patients, in particular, those with B-cell malignancies and on B-cell-targeting or depleting therapy. Patients with haematological malignancies should receive treatment for COVID-19 in accordance with the severity of their symptoms, but even mild infections should prompt early treatment with antiviral agents. The issue of de-isolation following COVID-19 infection and optimal time to treatment for haematological malignancies is discussed but remains an area with evolving data. This position statement is to be used in conjunction with advice from infectious disease, respiratory and intensive care specialists, and current guidelines from the National COVID-19 Clinical Evidence Taskforce and the New Zealand Ministry of Health and Cancer Agency Te Aho o Te Kahu COVID-19 Guidelines.
摘要：
尽管疫苗接种率普遍，我们生活在SARS-CoV-2的高传播中。尽管总体住院率正在下降，对于因血液恶性肿瘤而免疫功能低下的患者，严重感染的风险仍然很高。鉴于正在进行的大流行和多种治疗药物的发展，澳大利亚和新西兰血液学会的代表和传染病专家就关于血液疾病患者的COVID-19管理的共识立场声明进行了合作。我们建议对血液恶性肿瘤患者和治疗专家进行有关现有预防和治疗选择的教育，并继续接受适当的疫苗接种，记住血液病患者中发生的次优疫苗反应，特别是,那些患有B细胞恶性肿瘤和B细胞靶向或消耗治疗的患者。血液恶性肿瘤患者应根据其症状的严重程度接受COVID-19治疗，但即使是轻度感染，也应提示早期抗病毒药物治疗。讨论了COVID-19感染后的分离问题和血液恶性肿瘤的最佳治疗时间，但仍然是一个数据不断变化的领域。此立场声明将与传染病的建议结合使用，呼吸和重症监护专家，以及国家COVID-19临床证据工作组和新西兰卫生和癌症机构TeAhoTeKahuCOVID-19指南的现行指南。
